Melanoma News

For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.

The combination of atezolizumab plus bevacizumab demonstrates promising antitumour activity in patients with advanced mucosal melanoma while having a manageable safety profile, according to the results of a phase II study.

The status of sentinel lymph nodes (SLN) can help predict the course of the disease in patients with clinical stage IIB/C cutaneous melanoma, suggests a study.

Delays in the treatment of melanoma may worsen overall (OM) and melanoma-specific mortality (MSM), suggest the results of a recent study.

Individuals exposed to low-dose methotrexate risk developing melanoma, although the absolute risk increase remains very low, as shown in a recent meta-analysis.

Treatment with the combination of ribociclib plus binimetinib appears to be well tolerated and delivers modest clinical activity in patients with locally advanced or metastatic melanoma harbouring NRAS mutation, according to the results of a phase Ib/II study.

Taking aspirin daily appears to do nothing in terms of reducing the risk of cutaneous melanoma in older individuals, according to a study.

A compact device that incorporates high-resolution millimetre-wave imaging (HR-MMWI) can diagnose malignant skin lesions as accurately as clinical examination and other detection techniques, potentially cutting the number of unnecessary biopsies in half, as reported in a study.